BRPI0509079A - molécula de ácido nucléico, vetor, célula hospedeira, partìculas tipo vìrus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal - Google Patents
molécula de ácido nucléico, vetor, célula hospedeira, partìculas tipo vìrus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animalInfo
- Publication number
- BRPI0509079A BRPI0509079A BRPI0509079-2A BRPI0509079A BRPI0509079A BR PI0509079 A BRPI0509079 A BR PI0509079A BR PI0509079 A BRPI0509079 A BR PI0509079A BR PI0509079 A BRPI0509079 A BR PI0509079A
- Authority
- BR
- Brazil
- Prior art keywords
- hpv
- pharmaceutical compositions
- virus
- vlps
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
MOLéCULA DE áCIDO NUCLéICO, VETOR, CéLULA HOSPEDEIRA, PART CULAS TIPO VìRUS, MéTODO PARA PRODUZIR VLPs, VACINA, COMPOSIçõES FARMACêUTICAS, E , MéTODOS PARA EVITAR INFECçãO POR HPV E PARA INDUZIR UMA RESPOSTA IMUNE EM UM ANIMAL São providas moléculas de DNA sintéticas, codificando a proteína L1 do HPV 52. especificamente, a presente inveção provê polinucleotídeos codificando a proteína L1 do HPV 52, em que ditos polinuleotídeos são otimizados por códons para expressão de alto nível em uma célula de levedura. Em formar de realização alternativas da invenção, a sequência de nucleotídeo da molécula sintética é alterada para para eliminar os sinais de terminação de transcrição, que são reconhecidos pela levedura. As moléculas sintéticos podem ser usadas para produzir partículas tipo vírus (VLPs) do HPV 52 e para vacinas e composições farmacêuticas compreendendo as VLPs do HPV 52. As vacinas da presente invenção fornecem imunoprofilaxia eficaz contra infecção por papilomavírus, através da neutralização de anticorpo e imunidade mediada por célula e podem também ser usadas para tratamento das existentes infecções por HPV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55592604P | 2004-03-24 | 2004-03-24 | |
| PCT/US2005/009199 WO2005097821A1 (en) | 2004-03-24 | 2005-03-18 | Optimized expression of hpv 52 l1 in yeast |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0509079A true BRPI0509079A (pt) | 2007-08-21 |
| BRPI0509079B1 BRPI0509079B1 (pt) | 2020-05-19 |
| BRPI0509079B8 BRPI0509079B8 (pt) | 2021-07-06 |
Family
ID=34964085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0509079A BRPI0509079B8 (pt) | 2004-03-24 | 2005-03-18 | molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7700103B2 (pt) |
| EP (1) | EP1730175B1 (pt) |
| JP (1) | JP4833962B2 (pt) |
| KR (1) | KR101203403B1 (pt) |
| CN (1) | CN1934131B (pt) |
| AR (1) | AR048191A1 (pt) |
| AT (1) | ATE466022T1 (pt) |
| AU (1) | AU2005230907C1 (pt) |
| BR (1) | BRPI0509079B8 (pt) |
| CA (1) | CA2560487C (pt) |
| CY (2) | CY1110349T1 (pt) |
| DE (1) | DE602005020913D1 (pt) |
| DK (1) | DK1730175T3 (pt) |
| ES (1) | ES2343255T3 (pt) |
| FR (1) | FR15C0085I2 (pt) |
| HU (1) | HUS1500062I1 (pt) |
| IL (1) | IL178140A (pt) |
| LT (2) | LTPA2015050I1 (pt) |
| LU (1) | LU92903I2 (pt) |
| MY (1) | MY148656A (pt) |
| NL (1) | NL300777I1 (pt) |
| NO (2) | NO338055B1 (pt) |
| NZ (1) | NZ549898A (pt) |
| PL (1) | PL1730175T3 (pt) |
| PT (1) | PT1730175E (pt) |
| RU (1) | RU2373219C2 (pt) |
| SI (1) | SI1730175T1 (pt) |
| TW (1) | TWI349036B (pt) |
| WO (1) | WO2005097821A1 (pt) |
| ZA (1) | ZA200607575B (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| CN1869215B (zh) * | 2006-05-19 | 2012-07-04 | 长春百克生物科技股份公司 | 一种制备人乳头瘤病毒的病毒样颗粒的方法 |
| EP2129394B1 (en) | 2007-03-09 | 2012-06-20 | Merck Sharp & Dohme Corp. | Papillomavirus vaccine compositions |
| CN101440371B (zh) * | 2007-11-23 | 2012-09-05 | 上海泽润生物科技有限公司 | 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因 |
| MX2010005699A (es) * | 2007-11-23 | 2010-09-14 | Shanghai Zerun Biotechnology C | Genes que codifican para la proteina l1 mayor de la capside del virus del papiloma humano y uso de los mismos. |
| KR102085465B1 (ko) * | 2010-05-14 | 2020-03-05 | 박스알타 인코퍼레이티드 | 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법 |
| CA2799205A1 (en) | 2010-05-25 | 2011-12-01 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
| IN2013CN00536A (pt) | 2010-07-02 | 2015-07-03 | Univ Xiamen | |
| US8361720B2 (en) | 2010-11-15 | 2013-01-29 | Exact Sciences Corporation | Real time cleavage assay |
| EP2646559A2 (en) | 2010-12-03 | 2013-10-09 | MS Technologies, LLC | Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells |
| CN102154325B (zh) * | 2011-01-01 | 2013-08-21 | 上海生物制品研究所有限责任公司 | 针对人乳头瘤状病毒的疫苗及其制法和用途 |
| RU2445357C1 (ru) * | 2011-02-15 | 2012-03-20 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16 |
| RU2445358C1 (ru) * | 2011-02-15 | 2012-03-20 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18 |
| CN110484554B (zh) * | 2013-04-26 | 2024-04-16 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv52 l1蛋白的方法 |
| CN110592133A (zh) * | 2013-05-17 | 2019-12-20 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv31 l1蛋白的方法 |
| CA2927434C (en) | 2013-10-16 | 2022-07-19 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
| CN104878022A (zh) * | 2015-04-27 | 2015-09-02 | 段青姣 | 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用 |
| CN106701796B (zh) * | 2015-08-12 | 2021-11-16 | 北京康乐卫士生物技术股份有限公司 | 52型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
| CN109750049B (zh) * | 2017-11-07 | 2023-08-18 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒52亚型蛋白表达 |
| AR121292A1 (es) | 2020-02-14 | 2022-05-04 | Merck Sharp & Dohme | Vacuna contra hpv |
| CN114539365B (zh) * | 2020-11-26 | 2023-12-01 | 中国医学科学院基础医学研究所 | 一种改造的人乳头瘤病毒52型l1蛋白及其用途 |
| CN113073105B (zh) * | 2021-03-23 | 2023-06-13 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
| CN113549634B (zh) * | 2021-06-07 | 2023-03-31 | 郑州大学 | 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用 |
| TW202313658A (zh) | 2021-08-06 | 2023-04-01 | 美商默沙東有限責任公司 | Hpv疫苗 |
| CN118019547A (zh) | 2021-08-19 | 2024-05-10 | 默沙东有限责任公司 | 热稳定脂质纳米粒子及其使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1339729C (en) * | 1988-10-26 | 1998-03-17 | Wayne D. Lancaster | Human papillomavirus type 52 dna sequences and methods for employing thesame |
| IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
| JP2001512308A (ja) | 1997-02-07 | 2001-08-21 | メルク エンド カンパニー インコーポレーテッド | 合成ｈｉｖ ｇａｇ遺伝子 |
| JP4434479B2 (ja) | 1997-07-09 | 2010-03-17 | ザ・ユニバーシティ・オブ・クイーンズランド | 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法 |
| AU753391B2 (en) | 1998-08-14 | 2002-10-17 | Merck Sharp & Dohme Corp. | Protein delivery system using human papillomavirus virus-like particles |
| EA200100236A1 (ru) * | 1998-08-14 | 2001-08-27 | Мерк Энд Ко., Инк. | Способ очистки вирусных частиц, подобных вирусу папилломы человека |
| SE514982C2 (sv) * | 1999-09-30 | 2001-05-28 | Active Biotech Ab | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
| PT1212358E (pt) | 1999-08-25 | 2005-04-29 | Merck & Co Inc | Genes sinteticos de papilomavirus humano |
| US6436402B1 (en) | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
| DE60124918T2 (de) | 2000-07-21 | 2007-08-02 | Glaxo Group Ltd., Greenford | Kodon-optimierte papillomavirussequenzen |
| US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| KR101080628B1 (ko) * | 2003-03-24 | 2011-11-08 | 머크 샤프 앤드 돔 코포레이션 | 효모에서 ｈｐｖ 31 ｌ1의 최적 발현 |
| MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
| MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
-
2005
- 2005-03-18 AU AU2005230907A patent/AU2005230907C1/en active Active
- 2005-03-18 KR KR1020067019673A patent/KR101203403B1/ko active IP Right Grant
- 2005-03-18 US US10/594,064 patent/US7700103B2/en active Active
- 2005-03-18 DK DK05725933.5T patent/DK1730175T3/da active
- 2005-03-18 PL PL05725933T patent/PL1730175T3/pl unknown
- 2005-03-18 NZ NZ549898A patent/NZ549898A/en unknown
- 2005-03-18 CN CN2005800095956A patent/CN1934131B/zh active Active
- 2005-03-18 DE DE602005020913T patent/DE602005020913D1/de active Active
- 2005-03-18 TW TW094108431A patent/TWI349036B/zh active
- 2005-03-18 BR BRPI0509079A patent/BRPI0509079B8/pt active IP Right Grant
- 2005-03-18 MY MYPI20051180A patent/MY148656A/en unknown
- 2005-03-18 EP EP05725933A patent/EP1730175B1/en active Active
- 2005-03-18 SI SI200531052T patent/SI1730175T1/sl unknown
- 2005-03-18 RU RU2006137363/13A patent/RU2373219C2/ru active
- 2005-03-18 JP JP2007505032A patent/JP4833962B2/ja active Active
- 2005-03-18 PT PT05725933T patent/PT1730175E/pt unknown
- 2005-03-18 CA CA2560487A patent/CA2560487C/en active Active
- 2005-03-18 ES ES05725933T patent/ES2343255T3/es active Active
- 2005-03-18 AT AT05725933T patent/ATE466022T1/de active
- 2005-03-18 WO PCT/US2005/009199 patent/WO2005097821A1/en active Application Filing
- 2005-03-23 AR ARP050101174A patent/AR048191A1/es active IP Right Grant
-
2006
- 2006-09-11 ZA ZA200607575A patent/ZA200607575B/xx unknown
- 2006-09-17 IL IL178140A patent/IL178140A/en active IP Right Grant
- 2006-10-23 NO NO20064815A patent/NO338055B1/no active Protection Beyond IP Right Term
-
2009
- 2009-10-14 US US12/578,995 patent/US7744892B2/en active Active
-
2010
- 2010-07-26 CY CY20101100698T patent/CY1110349T1/el unknown
-
2015
- 2015-11-30 NL NL300777C patent/NL300777I1/nl unknown
- 2015-12-02 HU HUS1500062C patent/HUS1500062I1/hu unknown
- 2015-12-04 FR FR15C0085C patent/FR15C0085I2/fr active Active
- 2015-12-07 CY CY2015052C patent/CY2015052I1/el unknown
- 2015-12-08 LT LTPA2015050D patent/LTPA2015050I1/lt unknown
- 2015-12-08 LT LTPA2015050C patent/LTC1730175I2/lt unknown
- 2015-12-08 LU LU92903C patent/LU92903I2/xx unknown
-
2017
- 2017-01-20 NO NO2017005C patent/NO2017005I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0509079A (pt) | molécula de ácido nucléico, vetor, célula hospedeira, partìculas tipo vìrus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal | |
| BRPI0408639A (pt) | molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, método para produzir partìculas semelhantes a vìrus, vacina, composições farmacêuticas, e, métodos para prevenir a infecção por hpv e para induzir uma resposta imune em um animal | |
| BRPI0416393A (pt) | molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, métodos para produzir as mesmas, para prevenir infecção por hpv, e para induzir uma resposta imune em um animal, vacina, composições farmacêuticas, e, polipeptìdeo hpv58 l1 isolado e purificado | |
| BRPI0414845A (pt) | mólecula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, método para produzir as partìculas semelhantes a vìrus, vacina, composições farmacêuticas, e, métodos para prevenir infecção por hpv e para induzir uma resposta imune em um animal | |
| Kim et al. | Influenza virus: dealing with a drifting and shifting pathogen | |
| CN103732749A (zh) | 计算优化的宽反应性的h1n1流感抗原 | |
| CN102675471B (zh) | 猪口蹄疫病毒o型广谱多表位重组抗原及其应用 | |
| Zheng et al. | Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses | |
| BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
| Lee et al. | Progress and hurdles in the development of influenza virus-like particle vaccines for veterinary use | |
| JP2021534182A (ja) | 免疫原性組成物及びその使用 | |
| Su et al. | The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650 | |
| Rcheulishvili et al. | Designing multi-epitope mRNA construct as a universal influenza vaccine candidate for future epidemic/pandemic preparedness | |
| WO2009074861A3 (en) | Improved vaccine | |
| MX2022016287A (es) | Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas. | |
| HK1130664A1 (en) | Hepatitis c virus non structural fusion protein | |
| MX2022014248A (es) | Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas. | |
| CN102657864B (zh) | 一种口蹄疫疫苗的免疫佐剂及其应用 | |
| CN104630172B (zh) | 一种血吸虫谷胱甘肽‑s‑转移酶的突变体及其应用 | |
| CN104056266B (zh) | 新喋呤佐剂及含新喋呤佐剂的疫苗 | |
| Nuñez-Ortiz et al. | Immunostimulant properties of full-length and truncated Marinobacter algicola flagellins, and their effects against viral hemorrhagic septicemia virus (VHSV) in trout | |
| WO2005123121A3 (en) | Use of dna molecule as vaccine adjuvant | |
| RU2757013C2 (ru) | Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения | |
| Malik et al. | Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review | |
| Tavakoli et al. | Cloning and Expression of Recombinant Nucleoprotein of Influenza H1N1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) Free format text: ALTERADO DE: MERCK AND CO., INC. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: SCHERING CORPORATION, (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2576 DE 19/05/2020 QUANTO A QUALIFICACAO DO TITULAR E O TITULO. |